Fosun Fund has continued increasing its stake in Guoshengtang, with its ownership exceeding 10%

Since the beginning of this year,Gushengtang (2273.HK) has received multiple share purchases from Star Capital, a prominent investment institution.As of June 10, 2026, Star Capital’s stake in Gushengtang has increased to23.5071 million shareswith its ownership percentage rising to10.03%, and its holding size continues to climb, fullydemonstrating long-term institutional investors’ strong recognition of and confidence in the company’s value.

Star Capital’s continued buying stems from its full recognition of Gushengtang’s clear strategy and steady expansion. In recent years, the company has adhered to a"organic growth + external acquisitions"dual-engine growth strategy, continuously expanding its domestic and international business footprint, with notable success in mergers and integrations. Particularly in its international expansion, the company has achieved breakthrough progress. Taking the Singapore market as an example, by June 2026, Gushengtang operated a total of 26 clinics in Singapore; in Q1 2026, outpatient visits in the Singapore region approached 20,000, successfully validating the feasibility and replicability of its international expansion model and creating new room for long-term earnings growth.

Multiple leading brokerages are also optimistic about Gushengtang's growth prospects, issuing 'buy' and 'overweight' ratings.In April this year, JPMorgan noted in a research report that the company’s organic growth is accelerating, its Singapore operations continue to achieve milestone breakthroughs, and its internationalization strategy has entered a phase of accelerated execution. CMB International believes the company prioritizes growth as a core strategic focus, consistently driving both organic and inorganic expansion, and is well positioned to leverage the current favorable M&A environment to advance integration efforts domestically and overseas, highlighting its long-term growth potential.

Industry analysts note that Foresight Fund, a renowned long-term value investor, has continuously increased its stake—an action carrying strong signaling value for the market. Coupled with positive views from multiple brokerages, this strongly validates Gushengtang’s core competitive advantages in the high-quality traditional Chinese medicine sector. Going forward, as the company continues executing its dual-engine strategy of organic growth and external expansion and further scales up its overseas operations, it is poised to enter a new phase of high-quality development.

11K Views